



# TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

Head Off. : Institute of Urology, Sakri Road, Dhule - 424001

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311, 02562 - 245322/ 245995

14<sup>th</sup> August 2024,

To,

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai — 400 001

Dear Sir/Madam,

Script Code: 539428

**Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2024.**

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30<sup>th</sup> June 2024 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Wednesday, 14<sup>th</sup> August 2024 at A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai — 400079 at 12.00 p.m , in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

**For Tejnaksh Healthcare Limited**

**Dr. Ashish V. Rawandale**  
Managing Director  
DIN:- 02005733





# TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

Head Off. : Institute of Urology, Sakri Road, Dhule - 424001

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311, 02562 - 245322/ 245995

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2024

Amount Rs. in Lacs

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30,2024	March 31,2024	June 30,2023	March 31,2024
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
<b>1</b>	<b>REVENUE</b>				
(a)	Revenue from operations (net)	217.55	214.25	191.81	822.15
(b)	Other income	6.90	6.46	7.32	27.84
	<b>Total Revenue (I)</b>	<b>224.45</b>	<b>220.70</b>	<b>199.13</b>	<b>849.99</b>
<b>2</b>	<b>EXPENSES</b>				
(a)	Cost of Materials Consumed	1.10	5.98	3.85	15.78
(b)	Purchases of stock-in-trade	15.96	16.32	20.20	62.17
(c)	Changes in inventories of Stock-in-Trade	4.48	(7.65)	(0.91)	(9.86)
(d)	Employee benefits expense	19.88	20.31	20.92	79.33
(e)	Finance costs	11.76	14.97	16.73	68.59
(f)	Depreciation and amortization expense	20.00	19.69	20.12	80.02
(g)	Other expenses	73.02	70.16	95.96	310.80
	<b>Total Expenses (II)</b>	<b>146.20</b>	<b>139.78</b>	<b>176.88</b>	<b>606.83</b>
<b>3</b>	<b>Profit before tax (I) - (II)</b>	<b>78.25</b>	<b>80.92</b>	<b>22.25</b>	<b>243.16</b>
<b>4</b>	<b>Tax expense:</b>				
(a)	Current tax	15.82	15.30	0.59	40.92
(b)	Adjustment of tax relating to earlier periods	-	-	-	0.39
(c)	Deferred tax	3.88	5.08	5.30	20.60
	<b>Total Tax Expenses</b>	<b>19.69</b>	<b>20.37</b>	<b>5.89</b>	<b>61.91</b>
<b>5</b>	<b>Profit for the Period</b>	<b>58.56</b>	<b>60.55</b>	<b>16.37</b>	<b>181.25</b>
<b>6</b>	<b>OTHER COMPREHENSIVE INCOME</b>				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.62	1.21	0.42	2.48
	Income tax effect	(0.16)	(0.31)	(0.11)	(0.62)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-
	<b>Other Comprehensive income for the period, net of tax</b>	<b>0.46</b>	<b>0.91</b>	<b>0.32</b>	<b>1.86</b>
	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>	<b>59.02</b>	<b>61.46</b>	<b>16.68</b>	<b>183.10</b>
<b>7</b>	<b>Paid up Equity Share Capital (Face value Rs 5/- each.)</b>	1,015.68	1,015.68	1,015.68	1,015.68
<b>8</b>	<b>Basic and Diluted earnings per share (INR)</b>	0.29	0.30	0.08	0.89

*S. S. S. S.*





# TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

Head Off. : Institute of Urology, Sakri Road, Dhule - 424001

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311, 02562 - 245322/ 245995

## Notes:

- 1) The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Healthcare Limited ('the Company') for the quarter ended June 30, 2024 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 14, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3) The Company's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment the disclosure pertaining to segments is not applicable.
- 4) The figures of the last quarter are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the end of the third quarter of the previous financial year.
- 5) The figures for the corresponding previous periods have been regrouped / reclassified wherever necessary, to make them comparable.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733



Mumbai

August 14, 2024

**Limited Review Report on unaudited Standalone Financial Results of Tejnakh Healthcare Limited for the quarter ended 30 June 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Tejnakh Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Tejnakh Healthcare Limited ("the Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the



recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co.  
Chartered Accountants  
ICAI Firm Reg.No.102047W

*Aashish S. Kakaria*

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN: 24102915BKEKZK9877



Mumbai

14<sup>th</sup> August, 2024





# TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

Head Off. : Institute of Urology, Sakri Road, Dhule - 424001

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

## STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2024

Amount Rs. in Lacs

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30,2024	March 31,2024	June 30,2023	March 31,2024
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	<b>REVENUE</b>				
(a)	Revenue from operations (net)	312.39	292.20	302.51	1,217.51
(b)	Other income	7.22	7.05	8.04	30.66
	<b>Total Revenue (I)</b>	<b>319.60</b>	<b>299.25</b>	<b>310.55</b>	<b>1,248.17</b>
2	<b>EXPENSES</b>				
(a)	Cost of Materials Consumed	1.10	6.00	3.85	15.78
(b)	Purchases of stock-in-trade	31.16	28.58	38.18	124.33
(c)	Changes in inventories of Stock-in-Trade	2.90	(9.63)	(1.72)	(13.33)
(d)	Employee benefits expense	34.84	35.13	35.97	136.88
(e)	Finance costs	11.77	13.85	15.76	64.44
(f)	Depreciation and amortization expense	22.80	22.57	22.51	90.59
(g)	Other expenses	135.02	141.29	174.52	591.98
	<b>Total Expenses (II)</b>	<b>239.60</b>	<b>237.80</b>	<b>289.07</b>	<b>1,010.66</b>
3	<b>Profit before tax (I) - (II)</b>	<b>80.00</b>	<b>61.45</b>	<b>21.48</b>	<b>237.50</b>
4	<b>Tax expense:</b>				
(a)	Current tax	15.82	12.41	0.59	40.92
(b)	Adjustment of tax relating to earlier periods	-	0.31	-	1.01
(c)	Deferred tax	4.32	3.06	5.11	19.18
	<b>Total Tax Expenses</b>	<b>20.14</b>	<b>15.78</b>	<b>5.69</b>	<b>61.11</b>
5	<b>Profit for the year</b>	<b>59.87</b>	<b>45.67</b>	<b>15.79</b>	<b>176.40</b>
6	<b>OTHER COMPREHENSIVE INCOME</b>				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.78	0.68	0.81	3.12
	Income tax effect	(0.20)	(0.17)	(0.20)	(0.78)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-
	Other Comprehensive income for the year, net of tax	<b>0.58</b>	<b>0.51</b>	<b>0.61</b>	<b>2.33</b>
	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>	<b>60.45</b>	<b>46.18</b>	<b>16.40</b>	<b>178.73</b>
7	<b>Profit for the year attributable to:</b>				
	Equity holders of the parent	59.54	49.83	15.93	177.61
	Non-controlling interests	0.33	(4.16)	(0.14)	(1.21)

*L. K. Wadgaonkar*





# TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

Head Off. : Institute of Urology, Sakri Road, Dhule - 424001

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

8	<b>Other comprehensive income for the period attributable to:</b>				
	Equity holders of the parent				
	Non-controlling interests	0.55	0.17	0.54	2.21
		0.03	0.34	0.07	0.12
9	<b>Total comprehensive income for the period attributable to:</b>				
	Equity holders of the parent	60.09	50.00	16.47	179.82
	Non-controlling interests	0.36	(3.82)	(0.07)	(1.09)
10	<b>Paid up Equity Share Capital (Face value Rs 5/- each.)</b>	1,015.68	1,015.68	1,015.68	1,015.68
11	<b>Basic and Diluted earnings per share (INR)</b>	0.29	0.25	0.08	0.87

## Notes:

- 1) The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Healthcare Limited (the 'Parent'/'Group') and its subsidiaries (together referred to as the 'Group') for the quarter ended June 30, 2024 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 14, 2024. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.
- 2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3) The Group's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment the disclosure pertaining to segments is not applicable.
- 4) The figures of the last quarter are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the end of the third quarter of the previous financial year.
- 5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733



Mumbai

August 14, 2024

**Limited Review Report on unaudited consolidated financial results of Tejnakh Healthcare Limited for the quarter ended 30 June 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Tejnakh Healthcare Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnakh Healthcare Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (*Ind AS 34*) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Tejnakh Healthcare Limited and subsidiary Company - Tej Vedaant Healthcare Private Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.





6. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

7. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co.  
Chartered Accountants  
ICAI Firm Reg.No.102047W

*Aashish*

(Aashish S. Kakaria)  
Partner

Membership No.102915  
UDIN: 24102915BKEKZL8664



Mumbai  
14<sup>th</sup> August, 2024

